Parkinson's is not classified as an autoimmune disease, but the immune system does play a role in how it develops

Parkinson's disease is a neurological condition caused by the loss of dopamine-producing nerve cells in the brain. It is not an autoimmune disease, meaning your immune system is not attacking your own brain cells the way it does in conditions like rheumatoid arthritis or lupus. However, research over the past decade has shown that inflammation and immune activity are involved in Parkinson's, which is why the distinction matters for how doctors think about treatment.

The confusion arises because both autoimmune diseases and Parkinson's involve immune system activity. The difference is the mechanism: in autoimmune disease, your immune system mistakenly identifies your own cells as foreign and attacks them directly. In Parkinson's, the immune system becomes overactive in response to other triggers—possibly misfolded proteins, environmental toxins, or genetic factors—and this inflammation contributes to nerve cell death, but it is not the primary cause.

Key Takeaways

  • Parkinson's disease is not classified as autoimmune, but immune system inflammation does contribute to nerve cell loss in the brain.
  • In autoimmune diseases, the immune system directly attacks the body's own cells; in Parkinson's, inflammation is a secondary process triggered by other factors.
  • Researchers have found elevated levels of inflammatory markers and immune cells in the brains and blood of people with Parkinson's.
  • Understanding the immune component of Parkinson's has opened new research directions, though no immune-targeting treatments are standard care yet.

What the research shows about immune activity in Parkinson's

Studies have found that people with Parkinson's often have higher levels of inflammatory molecules in their cerebrospinal fluid and blood. Researchers have also observed that certain immune cells, called microglia, become overactive in the brains of people with Parkinson's. These cells normally clean up debris and dead cells, but when overactive, they can release substances that damage dopamine-producing neurons.

A landmark 2019 study published in Nature Neuroscience identified a specific immune pathway that may contribute to Parkinson's. Researchers found that a protein called alpha-synuclein—which accumulates abnormally in Parkinson's—can trigger immune cells to attack dopamine neurons. This does not make Parkinson's autoimmune in the traditional sense, but it does show that the immune system is part of the disease process.

Other research has examined whether people with autoimmune diseases have higher rates of Parkinson's. Some studies suggest a possible link, while others show no clear connection. The evidence is mixed, which is why scientists continue to investigate whether certain autoimmune conditions might increase Parkinson's risk in some people.

How inflammation differs from autoimmune attack

Inflammation is a general immune response to injury, infection, or irritation. It can be helpful in the short term but harmful if it becomes chronic. In Parkinson's, chronic inflammation in the brain appears to accelerate the loss of dopamine neurons, but the immune system is not specifically targeting those neurons as "foreign."

Autoimmune attack is different: the immune system produces antibodies or immune cells that specifically recognize and destroy the body's own cells. In autoimmune Parkinson's-like syndromes (a rare condition called autoimmune parkinsonism), the immune system does directly attack brain tissue, but this accounts for only a tiny fraction of Parkinson's cases and is treated very differently—often with immunosuppressive drugs.

Most people with Parkinson's do not have autoimmune parkinsonism. Their condition involves neurodegeneration driven by a combination of genetic factors, environmental exposures, and secondary immune set up—not primary immune attack.

Why this distinction matters for treatment

If Parkinson's were primarily autoimmune, doctors would use immunosuppressive medications to calm the immune system, the way they treat lupus or multiple sclerosis. Standard Parkinson's treatment focuses instead on replacing dopamine or protecting remaining dopamine neurons, using drugs like levodopa and carbidopa.

That said, the discovery of immune involvement has sparked new research into whether anti-inflammatory approaches might slow Parkinson's progression. Some studies are exploring whether common anti-inflammatory drugs, immune-modulating therapies, or drugs that calm microglial set up might help. None of these are standard treatments yet, and results have been mixed. Your neurologist can discuss whether any experimental approaches might be relevant to your situation.

Autoimmune parkinsonism: a rare look-alike condition

There is a rare condition called autoimmune parkinsonism that does involve direct immune attack on the brain. It can be caused by antibodies against specific brain proteins, such as NMDA receptors or GABA receptors. People with autoimmune parkinsonism may have symptoms that resemble Parkinson's—tremor, rigidity, slowness of movement—but the underlying cause is autoimmune, not neurodegenerative.

Autoimmune parkinsonism is diagnosed through blood tests that look for specific antibodies and sometimes through cerebrospinal fluid analysis. It is treated with immunosuppressive drugs, corticosteroids, or intravenous immunoglobulin (IVIG), and people can sometimes improve significantly with these treatments. If your symptoms came on suddenly or you have other autoimmune conditions, your doctor may test for autoimmune parkinsonism to rule it out.

What this means for living with Parkinson's

Understanding that immune inflammation plays a role in Parkinson's does not change how the condition is managed today, but it does offer hope for future treatments. Researchers are actively studying ways to reduce harmful inflammation while preserving the immune system's protective functions. Clinical trials are ongoing for anti-inflammatory and neuroprotective approaches.

If you have Parkinson's, staying informed about your diagnosis and any new treatment options is important. Talk with your neurologist about whether you might be a candidate for any clinical trials or emerging therapies. In the meantime, the established approaches—medication, physical therapy, speech therapy, and lifestyle changes—remain the most evidence-based ways to manage symptoms and maintain quality of life.

Frequently Asked Questions

Can I catch Parkinson's from someone else if it involves the immune system?

No. Parkinson's is not contagious. The immune involvement in Parkinson's is not an infection; it is an internal inflammatory process. You cannot catch it from another person, and having Parkinson's does not put others at risk.

If I have an autoimmune disease, am I more likely to develop Parkinson's?

The relationship is unclear. Some research suggests a possible link, but other studies do not. Having an autoimmune condition does not mean you will develop Parkinson's. If you have concerns, discuss your personal and family history with your doctor.

Will immunosuppressive drugs help my Parkinson's?

Standard immunosuppressive drugs are not used to treat typical Parkinson's disease. If you have autoimmune parkinsonism (a rare condition), immunosuppressive treatment may help. Your neurologist can determine which type of parkinsonism you have and recommend appropriate treatment.

Are there new treatments targeting inflammation in Parkinson's?

Researchers are studying anti-inflammatory and microglial-targeting approaches, but none are standard care yet. Ask your neurologist whether any clinical trials might be available in your area or whether you might be a candidate for emerging therapies.

How can I learn about I have autoimmune parkinsonism instead of Parkinson's disease?

Autoimmune parkinsonism is diagnosed through blood tests for specific antibodies and sometimes cerebrospinal fluid testing. If your symptoms came on suddenly or you have other autoimmune conditions, ask your doctor whether testing for autoimmune parkinsonism is appropriate for you.